Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Anthelminthic Agents

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

Tuberculosis

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HspX knock-out in Mycobacterium tuberculosis leads to shorter antibiotic treatment and lower relapse rate in a mouse model--a potential novel therapeutic target.

Tuberculosis (Edinburgh, Scotland)·2014

Same author

Persister populations of Mycobacterium tuberculosis in sputum that grow in liquid but not on solid culture media.

The Journal of antimicrobial chemotherapy·2013

Same author

Assessment of the Efficacy of New Anti-Tuberculosis Drugs.

The open infectious diseases journal·2013

Same author

Prevention of drug resistance by combined drug treatment of tuberculosis.

Handbook of experimental pharmacology·2012

Same author

Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings.

Journal of clinical microbiology·2012

Same author

Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling.

Future medicinal chemistry·2011

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

A new antituberculosis drug that selectively kills nonmultiplying Mycobacterium tuberculosis.

Denis A Mitchison¹

¹Division of Cellular & Molecular Microbiology, St. George's, University of London, Cranmer Terrace, London SW18 0RE, UK. dmitchis@sgul.ac.uk

Cell Host & Microbe

|March 11, 2008

Summary

A new rhodanine prodrug effectively targets nonmultiplying Mycobacterium tuberculosis (Mtb). This discovery offers a promising new weapon against tuberculosis, particularly for dormant bacterial infections.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Related Experiment Videos

Last Updated: Jul 6, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Area of Science:

Microbiology
Drug Discovery
Infectious Diseases

Background:

Mycobacterium tuberculosis (Mtb) exhibits tolerance to current drugs, especially in its non-replicating state.
Non-replicating Mtb poses a significant challenge for tuberculosis treatment and control strategies.
Developing agents effective against dormant Mtb is crucial for eradicating the disease.

Discussion:

Bryk et al. report on a novel rhodanine prodrug with activity against nonmultiplying Mtb.
This prodrug demonstrates potential for targeting persistent Mycobacterium tuberculosis populations.
The findings highlight the therapeutic potential of rhodanine derivatives in tuberculosis treatment.

Key Insights:

A novel rhodanine prodrug shows efficacy against non-replicating Mycobacterium tuberculosis.
This represents a significant advancement in developing new antituberculosis agents.
The drug's activity against dormant bacteria addresses a critical gap in current therapies.

Outlook:

This new drug could become a vital addition to the antituberculosis arsenal.
Further development may lead to improved treatment regimens for tuberculosis control.
The findings pave the way for new strategies against persistent Mtb infections.